Valneva SE Engages with Investors at Upcoming Conference
Valneva SE, a prominent specialty vaccine company, has announced its participation in a highly anticipated investor event. The management team will engage in one-on-one meetings with existing shareholders and seek new conversations with institutional investors during an upcoming conference.
Investor Meetings Scheduled
During the conference, which will occur soon, Valneva's leadership, including CEO Thomas Lingelbach and CFO Peter Bühler, will provide insights into the company's evolving commercial portfolio of vaccines. They expect a promising outlook for 2024 revenue, forecasting between €160 - €170 million. This presentation will address the pivotal developments in their clinical pipeline, including key updates on the Lyme disease vaccine's data readout.
Innovative Vaccine Development at Valneva
Valneva is dedicated to advancing public health through its innovative vaccine solutions. Specializing in prophylactic vaccines, the company adopts a targeted development approach to create effective treatments for infectious diseases. Their commitment is highlighted by their strong track record in taking vaccines from early R&D stages to market readiness.
Current Vaccine Offerings
Valneva currently markets three proprietary travel vaccines, which include notable products such as the world's first and only chikungunya vaccine. The revenues generated from these vaccines play a crucial role in funding the development of their pipeline candidates, which include partnerships with major pharmaceutical companies like Pfizer.
Future Prospects and Industry Leadership
The company is at the forefront of developing important vaccine candidates, including the only Lyme disease vaccine in advanced clinical stages. Furthermore, Valneva leads in innovative candidates targeting other critical health threats, such as the tetravalent Shigella vaccine and vaccines against the Zika virus.
Contact for Investor Relations
Interested investors and analysts may schedule a one-on-one meeting with Valneva’s investor relations team. The team is accessible through email for any inquiries. They are dedicated to transparency and fostering strong relationships with stakeholders.
About Valneva SE
Valneva SE focuses on delivering unique and impactful vaccine solutions to address unmet public health needs. With expertise spanning various vaccine modalities, the company strives to provide first-, best-, or only-in-class vaccine options. Their commitment to advancing vaccine development not only serves current health needs but also paves the way for future advancements.
Frequently Asked Questions
What is Valneva SE's main focus as a company?
Valneva SE specializes in developing, manufacturing, and commercializing vaccines for infectious diseases, targeting unmet medical needs.
When is the J.P. Morgan Healthcare Conference taking place?
The J.P. Morgan Healthcare Conference occurs during important dates in January, specifically from the 13th to the 15th.
How much revenue is Valneva SE expecting in 2024?
Valneva SE anticipates generating between €160 to €170 million in revenues from its commercial vaccine portfolio in 2024.
What vaccines does Valneva SE currently market?
Valneva markets three proprietary travel vaccines, including the world's first chikungunya vaccine.
How can investors reach Valneva's investor relations?
Investors can contact Valneva's investor relations department via email to schedule meetings and inquire further about the company's offerings.
